Fluocinolone acetonide micro-insert intravitreous implant - Alimera/EyePoint Pharmaceuticals

Drug Profile

Fluocinolone acetonide micro-insert intravitreous implant - Alimera/EyePoint Pharmaceuticals

Alternative Names: DF-277; FAI insert; Fluocinolone; Fluocinolone acetonide intravitreal implant; Fluocinolone acetonide intravitreal insert; Iluvien; Injectable micro-insert - Alimera Sciences/EyePoint Pharmaceuticals; Medidur implant; Medidur-FA; NSC-92339; Ophthalmic implant - Alimera Sciences/EyePoint Pharmaceuticals; YUTIQ

Latest Information Update: 20 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator pSivida Inc
  • Developer Alimera Sciences; EyePoint Pharmaceuticals; Hospital for Special Surgery; Johns Hopkins University; pSivida Inc
  • Class Anti-inflammatories; Antipruritics; Eye disorder therapies; Fluorinated steroids; Pregnadienes; Small molecules; Vasoconstrictors
  • Mechanism of Action Glucocorticoid receptor agonists; Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Uveitis

Highest Development Phases

  • Marketed Diabetic macular oedema
  • Registered Uveitis
  • Phase I Osteoarthritis
  • No development reported Dry age-related macular degeneration; Retinal vascular occlusion; Wet age-related macular degeneration

Most Recent Events

  • 06 Nov 2018 EyePoint Pharmaceuticals expects to launch fluocinolone acetonide implant for Uveitis in USA in the first quarter of 2019
  • 05 Nov 2018 Durasert™ three-year treatment licensed to Ocumension Therapeutics in China, Hong Kong, Macau and Taiwan for the treatment of Uveitis
  • 05 Nov 2018 Additional efficacy data from a III trial for Uveitis released by EyePoint Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top